MODE OF ACTION

A new mechanism of action for
immunotherapy development

 Our first-in-class myNEO Therapeutics algorithm (smORFin) identified a broad range of camyoRNAs, which are tumor-specific lncRNAs containing one or more small open reading frames. Translation of these smORFs leads to expression of small peptides (camyopeptides) within tumor cells that have great potential as ideal drug targets due to their specificity, abundance, and shared presence in cancer cells within and across patients.

myNEO Therapeutics applies its proprietary methods and algorithms to select the camyopeptides that contain epitopes of particular interest and suitability for immunotherapies (camyotopes™), which are presented by MHC-I complexes on the surface of the tumor cell and recognized by CD8+ T-cells, triggering strong and broad immune responses against the tumor.

As such, camyotopes enlarge the pool of new, unexploited targets to incorporate in novel immunotherapies for patients where alternative targets are absent or lacking immunogenicity. Moreover, due to their shared expression across patients, camyotopes could lead to the development of novel off-the-shelf cancer vaccines for a number of different tumor types. These targets offer clear advantages compared to other types of tumor antigens, including personalized mutational-driven targets as well as classical MAGE-A3-derived tumor associated antigens.

With large-scale data analyses and experimental studies myNEO Therapeutics has confirmed the expression levels of selected camyotope targets across different tumor types, and validated their clinical potential (as shown by the abundant but selective presence of camyotope peptides in cancer cells and their ability to promote highly immunogenic responses combined with successful organoid experiments).

MODE OF ACTION

A new mechanism of action for
immunotherapy development

 Our first-in-class myNEO Therapeutics algorithm (smORFin) identified a broad range of camyoRNAs, which are tumor-specific lncRNAs containing one or more small open reading frames. Translation of these smORFs leads to expression of small peptides (camyopeptides) within tumor cells that have great potential as ideal drug targets due to their specificity, abundance, and shared presence in cancer cells within and across patients.

myNEO Therapeutics applies its proprietary methods and algorithms to select the camyopeptides that contain epitopes of particular interest and suitability for immunotherapies (camyotopes™), which are presented by MHC-I complexes on the surface of the tumor cell and recognized by CD8+ T-cells, triggering strong and broad immune responses against the tumor.

As such, camyotopes enlarge the pool of new, unexploited targets to incorporate in novel immunotherapies for patients where alternative targets are absent or lacking immunogenicity. Moreover, due to their shared expression across patients, camyotopes could lead to the development of novel off-the-shelf cancer vaccines for a number of different tumor types. These targets offer clear advantages compared to other types of tumor antigens, including personalized mutational-driven targets as well as classical MAGE-A3-derived tumor associated antigens.

With large-scale data analyses and experimental studies myNEO Therapeutics has confirmed the expression levels of selected camyotope targets across different tumor types, and validated their clinical potential (as shown by the abundant but selective presence of camyotope peptides in cancer cells and their ability to promote highly immunogenic responses combined with successful organoid experiments).